Chemical formula: C₁₇H₁₇ClN₂O Molecular mass: 300.79 g/mol PubChem compound: 30768
Etifoxine is a nonbenzodiazepine anxiolytic agent and acts as a GABAA receptor positive allosteric modulator and as a ligand for translocator proteins. Both mechanisms are conjectured to contribute to its anxiolytic properties. Etifoxine primarily indicated for short-term management of adjustment disorder, specifically instances of situational depression accompanied by anxiety, such as stress-induced anxiety.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05BX03 | Etifoxine | N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BX Other anxiolytics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| STRESAM Capsule | MPI, EU: SmPC |
Etifoxine is an active ingredient of these brands:
France (FR)
Malta (MT)
South Africa (ZA)
Tunisia (TN)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
